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Abstract
Background: Haploinsufficiency of the GATA6 transcription factor gene was recently found to be the most
common cause of pancreatic agenesis, a rare cause of neonatal diabetes mellitus. Although most cases are
de novo, we describe three siblings with inherited GATA6 haploinsufficiency and the rare finding of parental
mosaicism.
Case Presentation: The proband was born at term with severe intrauterine growth restriction, the first
child of non-consanguineous parents. Diabetes occurred on day of life 1 with pancreatic exocrine insufficiency
noted at several months of age. Pancreatic agenesis with absent gallbladder was confirmed when he underwent
congenital diaphragmatic hernia and intestinal malrotation repair. A patent ductus arteriosus and pulmonary stenosis
were repaired in infancy. Neurocognitive development has been normal. A second pregnancy was terminated
due to tetralogy of Fallot and pulmonary hypoplasia secondary to congenital diaphragmatic hernia. The fetus
also demonstrated severe pancreatic hypoplasia, gallbladder agenesis and intestinal rotation abnormalities.
Despite severe hypoplasia, the pancreas demonstrated normal islet histology. Another sibling was found to
have multiple cardiac abnormalities, requiring procedural intervention. Given the proband’s spectrum of
congenital anomalies, Sanger sequencing of the GATA6 gene was performed, revealing a novel heterozygous
c.635_660del frameshift mutation (p.Pro212fs). The mutation is predicted to be pathogenic, resulting in
inclusion of a premature stop codon and likely degradation of the gene transcript by nonsense-mediated
decay. The abortus and the sibling with the cardiac defect were both found to have the mutation, while
the father and remaining sibling were negative. The mother, who is healthy with no evidence of diabetes
or cardiac disease, is mosaic for the mutation at a level of 11% in her peripheral leukocytes by next-generation
sequencing.
Conclusion: We highlight a rare mechanism of pancreatic agenesis, this being only the second report of parental
mosaicism for a GATA6 mutation and one of a handful of inherited cases. We also further define the phenotypic
variability of GATA6 haploinsufficiency, even in individuals carrying the same mutation. Mutations in GATA6 should be
strongly considered in cases of diabetes due to pancreatic hypoplasia or agenesis, and potentially affected family
members should be tested regardless of phenotype.
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Background
Although type 1 diabetes mellitus accounts for the vast
majority of pediatric diabetes, monogenic forms account
for up to 4% of cases [1, 2]. The latter are due to single
gene defects affecting pancreatic β-cell function, devel-
opment or survival and include neonatal diabetes melli-
tus (NDM). NDM is defined as diabetes occurring in the
first six months of life and occurs with an estimated fre-
quency of approximately 1:100 000 live births [2–5].
Both transient and permanent forms of NDM exist
(Table 1). Although clinically indistinguishable from
each other at presentation, most transient cases resolve
at a median age of 12 weeks but relapse in 50–60%
[6, 7]. Different genetic loci and genes are associated
with transient versus permanent NDM. Methylation ab-
normalities at chromosome 6q24 account for two thirds
of transient cases, while in permanent NDM, activating
mutations in ABCC8 and KCNJ11 are the most common
genetic defects in outbred populations and EIF2AK3 is
the most frequent in consanguineous groups [3, 7].
KCNJ11 and ABCC8 encode the KIR6.2 and SUR1 sub-
units of the KATP channel, respectively, which links glu-
cose metabolism to insulin secretion. EIF2AK3 encodes
a kinase involved in regulating the endoplasmic
reticulum stress response to misfolded proteins [8, 9].
Although the mechanism causing diabetes is unclear, de-
fects in EIF2AK3 may cause ER stress in the β-cell from
misfolded proteins due to the high demand for insulin
secretion, eventually leading to β-cell apoptosis. Alterna-
tively, diabetes may be linked to reduced β-cell prolifera-
tion with abnormal insulin trafficking and secretion, as
observed in EIF2AK3 knockout mice [9].
Permanent NDM can also result from pancreatic agen-
esis or hypoplasia, which has been linked to mutations
in transcription factors important for pancreatic and β-
cell development. The most common of these is GATA6
[10]. Other causes include mutations in PDX1 and the
PTF1A enhancer causing isolated abnormal pancreas de-
velopment, while mutations in PTF1A, RFX6, HNF1B
and GATA4 are associated with both pancreatic and
extra-pancreatic abnormalities (Table 2) [11–16]. GATA6
is one of a family of evolutionarily conserved transcrip-
tion factors recognizing the A/T-GATA-A/G consensus
sequence, with key roles in the development and differ-
entiation of multiple cell lineages and tissues [17, 18].
Heterozygous inactivating mutations in GATA6 were
identified through a whole exome sequencing strategy in
15/27 (56%) individuals with pancreatic agenesis, defined
as NDM requiring insulin treatment and exocrine pan-
creatic insufficiency requiring enzyme replacement. This
is a syndromic form of NDM associated with extra-
pancreatic features including cardiac, hepatobiliary,
gastrointestinal, neurocognitive and other endocrine in-
volvement. Since its initial discovery, the phenotypic
spectrum of GATA6 haploinsufficiency in humans has
proven to be more diverse than initially appreciated, and
although the initial cases were de novo, several instances
of inherited GATA6 mutations have now been described
[19–21]. This report describes three siblings with inher-
ited GATA6 haploinsufficiency and the rare finding of
parental mosaicism.
Case presentation
The proband was born at 37 weeks gestation after a
pregnancy complicated by severe intrauterine growth re-
striction, reflected in the birth weight of 1.74 kg (<3rd
percentile, −4 standard deviations). He was the first child
of non-consanguineous parents of French Canadian
background. Hyperglycemia occurred within the first
12 h of life and neonatal diabetes mellitus was diag-
nosed. An initial ultrasound visualized only the head of
the pancreas, suggesting pancreatic hypoplasia. He was
placed on subcutaneous insulin therapy with adequate
glycemic control. Moderate valvular pulmonary stenosis
and a patent ductus arteriosus (PDA) were also diag-
nosed and valvuloplasty was performed in the neonatal
period.
At several months of age, recurrent episodes of
hypoglycemia with decreasing insulin requirements
began to occur. He was diagnosed with pancreatic exo-
crine insufficiency (PI) based on the recurrent
hypoglycemia, poor weight gain and low stool fecal
Table 1 Key genes associated with neonatal diabetes mellitus
Gene Location Inheritance Clinical features
PLAGL1, HYMAI 6q24 Variable
(imprinting)
Transient NDM
± Macroglossia,
± Umbilical Hernia,
± Other features if
part of generalized
hypomethylation
syndrome
KCNJ11 11p15.1 De novo,
Dominant or
Recessive
Permanent or Transient
NDM, ± Developmental
delay, epilepsy, neonatal
diabetes (DEND) syndrome
ABCC8 11p15.1 De novo,
Dominant or
Recessive
Transient or Permanent
NDM, ± DEND syndrome
EIF2AK3 6q22.1 Recessive Wolcott-Rallison Syndrome:
Permanent NDM
Short stature
Bone dysplasia
Hepatic dysfunction
INS 11p15.5 Recessive Isolated permanent or
transient NDM
GCK 7p15-p13 Recessive Isolated permanent NDM
The most common genes associated with neonatal diabetes mellitus are
described with key clinical features and mode of inheritance. Adapted from
[2]. Genes associated with abnormal pancreas development are described
in Table 2
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elastase, leading to initiation of pancreatic enzyme re-
placement. At 8 months of age, he was readmitted for
severe failure to thrive and hypoglycemia secondary to
inadequately treated PI, heart failure from the persistent
PDA and a previously undiagnosed congenital diaphrag-
matic hernia. Intestinal malrotation was also noted. His
medical management was optimized and he underwent
repair of the PDA, diaphragmatic hernia and intestinal
malrotation. At the time of surgery, no pancreatic tissue
or gallbladder could be identified, demonstrating both
pancreatic and gallbladder agenesis.
Despite improvement in his nutritional and overall
health status, he continued to have episodes of early
morning hypoglycemia, presumably due to deficient
glucagon secretion. This was managed with feeds of
uncooked cornstarch to provide a source of slowly-
released glucose while on insulin injections and,
when transitioned to pump therapy, with low basal
insulin rates. Control of both the diabetes and exo-
crine insufficiency have been adequate with no evi-
dence of malabsorption. There has been no clinical
evidence of other endocrine dysfunction and thyroid
function testing has been normal. He has also dem-
onstrated appropriate neurocognitive development as
of 9 years of age. Previous testing of the PDX1 gene,
a recognized cause of pancreatic agenesis (Table 2)
as well as broader genetic analysis through the
1,000,000 Single Nucleotide Polymorphism project
were unrevealing.
A second pregnancy was terminated at 20 weeks due
to complex congenital heart disease. Examination of the
abortus revealed a male fetus with tetralogy of Fallot,
congenital diaphragmatic hernia, severe pancreatic hypo-
plasia, gallbladder agenesis and intestinal non-rotation
(Fig. 1, individual IIB). Subsequently, two male infants
were born. The youngest child was found to have a PDA
requiring procedural intervention, left pulmonary artery
stenosis, and moderate atrial septal defect (Fig. 1, indi-
vidual IID). Neither the remaining sibling nor either
parent have any clinical evidence of diabetes, pancreatic
exocrine insufficiency or cardiac disease.
Methods
GATA6 sequencing
Genomic DNA was extracted from peripheral leukocytes
using standard procedures. Exons 2–7 and the exon/in-
tron boundaries of the GATA6 gene were analyzed by
Sanger sequencing as described previously. Exon 1 is a
non-coding exon and was not sequenced [10]. Sequen-
cing reactions were run on an ABI3730 capillary
machine (Applied Biosystems, Warrington, U.K.) and
analyzed using Mutation Surveyor v4.0.6 (SoftGenetics,
State College, PA) (GATA6 nucleotide reference
NM_005257.3). Allele frequency was quantified by next-
generation sequencing as previously described [22].
Histology
Immunohistochemistry and staining for hematoxylin,
phloxine, saffron were performed using standard proce-
dures on slides of pancreatic tissue obtained at autopsy
from the abortus (Fig. 1, individual IIB). For the immu-
nohistochemistry, antibodies were used to detect insulin,
glucagon and somatostatin.
Table 2 Genes associated with neonatal diabetes mellitus and abnormal pancreas development
Gene Location Inheritance Clinical features Reference
PDX1 13q12.1 Recessive IUGR,
Pancreatic agenesis,
Permanent NDM, PI
[11]
PTF1A enhancer 10p12.2 Recessive IUGR, Pancreatic agenesis,
Permanent NDM, PI
[12]
PTF1A 10p12.2 Recessive IUGR,
Pancreatic agenesis,
Permanent NDM, variable PI,
Cerebellar
hypoplasia/aplasia
[13]
RFX6 6q22.1 Recessive IUGR, Annular/hypoplastic pancreas,
Permanent NDM,
Chronic diarrhea,
Biliary and intestinal abnormalities
[14, 32–35]
HNF1B 17q21.3 Dominant IUGR,
Pancreas hypoplasia,
Renal cysts
[15]
GATA4 8p23.1 Dominant IUGR,
Pancreatic hypoplasia/agenesis,
Congenital heart defects,
Developmental delay
[16]
Genes in addition to GATA6 associated with both isolated diabetes and extra-pancreatic features are described with key clinical features and mode of inheritance
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Results
Given the similarity between the proband’s spectrum of
congenital anomalies and the clinical phenotype of
GATA6 mutations, Sanger sequencing of exons 2–7 of the
GATA6 gene was performed in peripheral leukocytes. A
novel c.635_660del frameshift mutation (p.Pro212fs) was
identified in the proband. The mutation is located in exon
2, within the transcriptional activation domain, and is pre-
dicted to result in inclusion of a premature stop codon
and likely degradation of the gene transcript by nonsense-
mediated decay (Fig. 2). The mother, the abortus and the
sibling with the congenital heart defect were also found to
carry the mutation (Fig. 1). Notably, the mother, who has
no clinical evidence of diabetes, including gestational dia-
betes or cardiac disease, was found to be mosaic for the
mutation (Fig. 1, individual IA). This was confirmed and
quantified by next-generation sequencing, revealing 11%
mosaicism in peripheral blood. The father and the
remaining sibling’s testing were negative.
Histological analysis of the pancreas from the abortus
(Fig. 1, individual IIB) demonstrated well-formed islets
despite severe pancreatic hypoplasia (Fig. 3). The major-
ity of islet cells stained positive for insulin and were
surrounded by smaller populations of glucagon and
somatostatin positive cells, demonstrating normal islet
morphology.
Discussion
We describe three siblings heterozygous for the same
GATA6 mutation inherited via parental mosaicism, yet
Fig. 1 Family Pedigree. The proband (II-A) and abortus (II-B) have multiple congenital anomalies including severe pancreatic agenesis/hypoplasia,
while one sibling (II-D), also heterozygous for the same mutation, has isolated congenital cardiac anomalies including a PDA, left pulmonary
artery stenosis, moderate atrial septal defect. The father and remaining sibling are negative for the mutation. The genotypes are provided below
each symbol, N denotes the wildtype allele
Fig. 2 Genomic and protein positions of the novel GATA6 mutation. a Exons 2 to 7 with the location of the novel deletion described are shown.
b The frameshift resulting from the deletion is shown with its location in the transcriptional activation domain. The numbers refer to the amino
acid position of the latter domain and the DNA-binding zinc fingers (ZnF)
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with widely different manifestations, further defining the
clinical phenotype associated with this rare disease.
Since the initial report of heterozygous GATA6 muta-
tions as the most common cause of pancreatic agenesis
or hypoplasia, a much greater degree of phenotypic vari-
ability has been recognized for both pancreatic and
extra-pancreatic features [10, 19]. Diabetes mellitus is
the most common pancreatic feature in 98% of cases
(Table 3). Although the majority of cases present with
NDM, in others diabetes develops later in life or has yet to
occur by adulthood. Similarly, although clinical PI has
been reported in 81% of cases, subclinical PI and normal
exocrine function have also been described (Table 3)
[10, 19, 23]. Of the extra-pancreatic features, cardiac
defects are the most common, in 88% of cases, although
gastrointestinal, hepatobiliary, neurodevelopmental and
Fig. 3 Islet morphology is preserved with appropriate distribution of insulin- and glucagon-positive cells despite severe pancreas hypoplasia.
Pancreas sections from individual II-B in Fig. 1 were stained using haematoxylin, phloxine and saffron staining (a), and immunohistochemistry
for insulin, glucagon and somatostatin (b to d). Islets were identified (a) demonstrating normal morphology with central insulin (b), peripheral
glucagon (c) and somatostatin staining (d). All images were photographed at 200× magnification
Table 3 Phenotypic spectrum associated with GATA6 haploinsufficiency
Clinical features Spectrum and severity Patients with GATA6
mutation, N = 41 (%)
Pancreatic Features
Diabetes Mellitus Neonatal/adult-onset Total 40/41 (98),
NDM 33/41 (81)a,
Child-onset 4/41 (10)b,
Adult-onset 3/41 (7)
Exocrine Insufficiency Clinical/subclinicald Total 33/37 (89)c,
Clinical 30/37 (81)
Extra-Pancreatic Features
Cardiac Isolated septal defect/multiple complex defects 36/41 (88)
Hepatobiliary Gallbladder atresia, biliary atresia 13/41 (32)
Gastrointestinal Umbilical hernia, diaphragmatic hernia, intestinal malrotation 8/41 (20)
Other Endocrine Hypothyroidism, pituitary agenesis 7/41 (17)
Neurocognitive Developmentally appropriate/mild learning difficulties/severe developmental delay 13/41 (32)
Genitourinary Bicornuate uterus, hydronephrosis, hydroureter 2/41 (5)
Summary of the pancreatic and extra-pancreatic features of the published cases to date, demonstrating the variability of the phenotype [10, 19–21, 23–29]. aNDM group
includes one case of transient NDM, bchildhood-onset group includes one case of impaired glucose tolerance in adolescence, cfour cases were excluded
as no information on exocrine insufficiency was provided, dsubclinical was defined as low fecal elastase or positive fecal fat in the absence of clinical
symptoms or need for pancreatic enzyme replacement
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other endocrine involvement have also been reported
(Table 3) [10, 19–21, 23–29]. The family described here il-
lustrates this clinical variability. The proband has NDM
and PI, with significant cardiothoracic, gastrointestinal
and biliary involvement. A similar phenotype was seen in
the second affected sibling whereas in contrast, the third
sibling has isolated cardiac involvement. Thus, GATA6
haploinsufficiency needs to be strongly considered as a
potential cause in cases of diabetes secondary to abnormal
pancreas development and, if confirmed, a thorough,
multi-system assessment, particularly cardiac, should be
performed to evaluate for other abnormalities. Consider-
ation should also be given to screening for glycemic ab-
normalities in those whom diabetes has not yet developed.
Although most cases of GATA6 mutations are de novo,
several cases of dominant inheritance have been reported
[10, 19]. The family described here is notable for being
amongst these inherited cases and moreover, is only the
second report of parental mosaicism [19]. In the previous
report, the parent was known to have a congenital heart
defect, whereas in our case the mother has no known car-
diac abnormalities or pancreatic phenotype. Presumably
differing levels of tissue mosaicism is key. Since three out
of four offspring inherited the mutation, the level of mo-
saicism is likely significantly higher in the germline com-
pared to other tissues in our case given the absence of
other system involvement and almost certainly higher
than the 11% detected in peripheral blood. Accordingly,
testing of parents and other potentially affected family
members should be performed, even in individuals with-
out an obvious clinical phenotype.
The mechanism underlying the variable expressivity of
GATA6 haploinsufficiency remains unclear with no obvi-
ous genotype-phenotype relationship [19]. Histologically,
grossly preserved islet morphology was observed, which
contrasts with murine models demonstrating abnormal
morphogenesis with failure of progenitor cells to differ-
entiate into endocrine and exocrine lineages (Fig. 3).
However, humans appear to have greater sensitivity to
GATA6 gene dosage as both Gata4 alleles in addition to
at least one Gata6 allele must be inactivated in mice to
cause pancreatic abnormalities [30, 31]. Although not ex-
plored in this report, at a molecular level, there are several
potential mechanisms. In vitro studies have shown that
missense mutations affecting highly conserved zinc finger
residues result in failure to bind target promoters in lucif-
erase reporter promoter assays [10, 19, 27]. Given the
location of the novel frameshift mutation described
here in the transactivation domain, there could be an
impact on downstream genetic targets through altered
binding of co-regulatory factors. However, the most
likely explanation is that the introduction of a prema-
ture termination codon results in a reduction in
GATA6 mRNA transcript levels through nonsense-
mediated decay, as previously described [26]. Variable
efficiency of this decay in different tissues could con-
tribute to the phenotypic variability. Modifier genes,
epigenetic mechanisms and environmental factors rep-
resent other potential mechanisms that could also
contribute to the variability associated with GATA6
heterozygous mutations.
Conclusions
Heterozygous mutations in the GATA6 transcription
factor gene are the most common cause of neonatal
diabetes due to pancreatic agenesis. We describe three
siblings heterozygous for the same GATA6 mutation
inherited via parental mosaicism, a rare occurrence.
Their markedly different manifestations illustrate both
the importance of GATA6 for pancreas development as
well as the phenotypic variability of GATA6 haploinsuffi-
ciency. Elucidating the mechanisms underlying the
phenotype and its variability will improve our under-
standing of pancreas development and may provide
insights into the mechanisms underlying other forms of
abnormal pancreas development and neonatal diabetes.
Abbreviations
IUGR: intrauterine growth restriction; NDM: neonatal diabetes mellitus;
PDA: patent ductus arteriosus; PI: pancreatic exocrine insufficiency
Acknowledgments
The authors thank the family who participated in this study. We also thank
A. Cuellar for his technical assistance regarding the immunohistochemistry.
Funding
JJM receives support from the Dr. Eleanor Mackenzie Harpur Pediatric
Endowment Fund. The genetic testing in this report was funded by
the Wellcome Trust via a Senior Investigator Award to SE. EDF is a
Naomi Berrie Fellow in Diabetes Research. SEF has a Sir Henry Dale
Fellowship jointly funded by the Wellcome Trust and the Royal Society
(Grant Number 105636/Z/14/Z).
Availability of data and materials
The anonymized data analyzed during the current study is available from
the corresponding author on reasonable request. Primer sequences used
for GATA6 sequencing are available in reference 10 and its supplementary
information files.
Authors’ contributions
JJM conceived of the study. GATA6 testing of the proband and family was
coordinated by JJM and DY. SE, EDF and SF carried out the genetic analysis.
MB performed and oversaw the histological analysis. DY wrote and JJM
revised the manuscript. All authors read and approved the final manuscript.
Authors’ information
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Written informed consent for publication of their clinical details and/or
clinical images was obtained from the parents of the patients. Copies of
the consent forms are available for review by the Editor of this journal.
Yau et al. Diagnostic Pathology  (2017) 12:1 Page 6 of 7
Ethics approval and consent to participate
The need for ethics approval from the institutional REB was waived as per
provincial ethics and legal requirements. Consent was obtained as outlined
above.
Author details
1Division of Pediatric Endocrinology Montreal Children’s Hospital, McGill
University Health Centre, 1001 Boulevard Decarie, Montreal H4A 3J1, Quebec,
Canada. 2Institute of Biomedical and Clinical Science, University of Exeter
Medical School, Barrack Road, Exeter EX2 5DW, UK. 3Department of
Pathology Montreal Children’s Hospital, McGill University Health Centre, 1001
Boulevard Decarie, Montreal H4A 3J1, Quebec, Canada.
Received: 1 September 2016 Accepted: 8 December 2016
References
1. Craig ME, Jefferies C, Dabelea D, Balde N, Seth A, Donaghue KC. Definition,
epidemiology, and classification of diabetes in children and adolescents.
Pediatr Diabetes. 2014;15 Suppl 20:4–17.
2. Rubio-Cabezas O, Hattersley AT, Njølstad PR, Mlynarski W, Ellard S, White N,
Chi DV, Craig ME. The diagnosis and management of monogenic diabetes
in children and adolescents. Pediatr Diabetes. 2014;15 Suppl 20:47–64.
3. De Franco E, Flanagan SE, Houghton JA, Lango Allen H, Mackay DJ, Temple IK,
Ellard S, Hattersley AT. The effect of early, comprehensive genomic testing on
clinical care in neonatal diabetes: an international cohort study. Lancet. 2015;
386:957–63.
4. Grulich-Henn J, Wagner V, Thon A, Schober E, Marg W, Kapellen TM,
Haberland H, Raile K, Ellard S, Flanagan SE, et al. Entities and frequency of
neonatal diabetes: data from the diabetes documentation and quality
management system (DPV). Diabet Med. 2010;27:709–12.
5. Iafusco D, Massa O, Pasquino B, Colombo C, Iughetti L, Bizzarri C, Mammi C,
Lo Presti D, Suprani T, Schiaffini R, et al. Minimal incidence of neonatal/
infancy onset diabetes in Italy is 1:90,000 live births. Acta Diabetol.
2012;49:405–8.
6. Shield JP, Temple IK, Sabin M, Mackay D, Robinson DO, Betts PR, Carson DJ,
Cave H, Chevenne D, Polak M. An assessment of pancreatic endocrine
function and insulin sensitivity in patients with transient neonatal diabetes
in remission. Arch Dis Child Fetal Neonatal Ed. 2004;89:F341–3.
7. Temple IK, Gardner RJ, Mackay DJ, Barber JC, Robinson DO, Shield JP.
Transient neonatal diabetes: widening the understanding of the
etiopathogenesis of diabetes. Diabetes. 2000;49:1359–66.
8. Karges B, Meissner T, Icks A, Kapellen T, Holl RW. Management of diabetes
mellitus in infants. Nat Rev Endocrinol. 2012;8:201–11.
9. Julier C, Nicolino M. Wolcott-rallison syndrome. Orphanet J Rare Dis.
2010;5:29.
10. Lango Allen H, Flanagan SE, Shaw-Smith C, De Franco E, Akerman I, Caswell R,
nternational Pancreatic Agenesis Consortium, Ferrer J, Hattersley AT, Ellard S.
GATA6 haploinsufficiency causes pancreatic agenesis in humans. Nat Genet.
2011;44:20–2.
11. Stoffers DA, Zinkin NT, Stanojevic V, Clarke WL, Habener JF. Pancreatic
agenesis attributable to a single nucleotide deletion in the human IPF1
gene coding sequence. Nat Genet. 1997;15:106–10.
12. Weedon MN, Cebola I, Patch AM, Flanagan SE, De Franco E, Caswell R,
Rodriguez-Segui SA, Shaw-Smith C, Cho CH, Lango Allen H, et al. Recessive
mutations in a distal PTF1A enhancer cause isolated pancreatic agenesis.
Nat Genet. 2014;46:61–4.
13. Sellick GS, Barker KT, Stolte-Dijkstra I, Fleischmann C, Coleman RJ,
Garrett C, Gloyn AL, Edghill EL, Hattersley AT, Wellauer PK, et al.
Mutations in PTF1A cause pancreatic and cerebellar agenesis.
Nat Genet. 2004;36:1301–5.
14. Concepcion JP, Reh CS, Daniels M, Liu X, Paz VP, Ye H, Highland HM, Hanis CL,
Greeley SA. Neonatal diabetes, gallbladder agenesis, duodenal atresia, and
intestinal malrotation caused by a novel homozygous mutation in RFX6.
Pediatr Diabetes. 2014;15:67–72.
15. Yorifuji T, Kurokawa K, Mamada M, Imai T, Kawai M, Nishi Y, Shishido S,
Hasegawa Y, Nakahata T. Neonatal diabetes mellitus and neonatal
polycystic, dysplastic kidneys: Phenotypically discordant recurrence of a
mutation in the hepatocyte nuclear factor-1beta gene due to germline
mosaicism. J Clin Endocrinol Metab. 2004;89:2905–8.
16. Shaw-Smith C, De Franco E, Lango Allen H, Batlle M, Flanagan SE, Borowiec M,
Taplin CE, van Alfen-van der Velden J, Cruz-Rojo J, Perez de Nanclares G, et al.
GATA4 mutations are a cause of neonatal and childhood-onset diabetes.
Diabetes. 2014;63:2888–94.
17. Viger RS, Guittot SM, Anttonen M, Wilson DB, Heikinheimo M. Role of the
GATA family of transcription factors in endocrine development, function,
and disease. Mol Endocrinol. 2008;22:781–98.
18. Minami K. GATA transcription factors: New key regulators in pancreas
organogenesis. J Diab Investig. 2013;4:426–7.
19. De Franco E, Shaw-Smith C, Flanagan SE, Shepherd MH, International NDM
Consortium, Hattersley AT, Ellard S. GATA6 mutations cause a broad
phenotypic spectrum of diabetes from pancreatic agenesis to adult-onset
diabetes without exocrine insufficiency. Diabetes. 2013;62:993–7.
20. Bonnefond A, Sand O, Guerin B, Durand E, De Graeve F, Huyvaert M,
Rachdi L, Kerr-Conte J, Pattou F, Vaxillaire M, et al. GATA6 inactivating
mutations are associated with heart defects and, inconsistently, with
pancreatic agenesis and diabetes. Diabetologia. 2012;55:2845–7.
21. Yorifuji T, Kawakita R, Hosokawa Y, Fujimaru R, Yamaguchi E, Tamagawa N.
Dominantly inherited diabetes mellitus caused by GATA6 haploinsufficiency:
variable intrafamilial presentation. J Med Genet. 2012;49:642–3.
22. Ellard S, Lango Allen H, De Franco E, et al. Improved genetic testing for
monogenic diabetes using targeted next-generation sequencing.
Diabetologia. 2013;56:1958–63.
23. Catli G, Abaci A, Flanagan SE, De Franco E, Ellard S, Hattersley A, Guleryuz H,
Bober E. A novel GATA6 mutation leading to congenital heart defects and
permanent neonatal diabetes: a case report. Diab Metab. 2013;39:370–4.
24. Gong M, Simaite D, Kuhnen P, Heldmann M, Spagnoli F, Blankenstein O,
Hubner N, Hussain K, Raile K. Two novel GATA6 mutations cause childhood-
onset diabetes mellitus, pancreas malformation and congenital heart
disease. Horm Res Paediatr. 2013;79:250–6.
25. Eifes S, Chudasama KK, Molnes J, Wagner K, Hoang T, Schierloh U, Rocour-
Brumioul D, Johansson S, Njolstad PR, de Beaufort C. A novel GATA6 mutation in
a child with congenital heart malformation and neonatal diabetes. Clin Case Rep.
2013;1:86–90.
26. Suzuki S, Nakao A, Sarhat AR, Furuya A, Matsuo K, Tanahashi Y, Kajino H,
Azuma H. A case of pancreatic agenesis and congenital heart defects with
a novel GATA6 nonsense mutation: evidence of haploinsufficiency due to
nonsense-mediated mRNA decay. Am J Med Genet A. 2014;164A:476–9.
27. Chao CS, McKnight KD, Cox KL, Chang AL, Kim SK, Feldman BJ. Novel
GATA6 mutations in patients with pancreatic agenesis and congenital heart
malformations. PLoS One. 2015;10:e0118449.
28. Tuhan H, Catli G, Anik A, Ozmen D, Turkmen MA, Bober E, Abaci A. Neonatal
diabetes mellitus due to a novel mutation in the GATA6 gene accompanying
renal dysfunction: a case report. Am J Med Genet A. 2015;167A:925–7.
29. Stanescu DE, Hughes N, Patel P, De Leon DD. A novel mutation in GATA6
causes pancreatic agenesis. Pediatr Diabetes. 2015;16:67–70.
30. Carrasco M, Delgado I, Soria B, Martin F, Rojas A. GATA4 and GATA6 control
mouse pancreas organogenesis. J Clin Invest. 2012;122:3504–15.
31. Xuan S, Borok MJ, Decker KJ, Battle MA, Duncan SA, Hale MA, Macdonald RJ,
Sussel L. Pancreas-specific deletion of mouse Gata4 and Gata6 causes
pancreatic agenesis. J Clin Invest. 2012;122:3516–28.
32. Chappell L, Gorman S, Campbell F, Ellard S, Rice G, Dobbie A, Crow Y.
A further example of a distinctive autosomal recessive syndrome
comprising neonatal diabetes mellitus, intestinal atresias and gall bladder
agenesis. Am J Med Genet A. 2008;146A:1713–7.
33. Mitchell J, Punthakee Z, Lo B, Bernard C, Chong K, Newman C, Cartier L,
Desilets V, Cutz E, Hansen IL, et al. Neonatal diabetes, with hypoplastic
pancreas, intestinal atresia and gall bladder hypoplasia: search for the aetiology
of a new autosomal recessive syndrome. Diabetologia. 2004;47:2160–7.
34. Smith SB, Qu HQ, Taleb N, Kishimoto NY, Scheel DW, Lu Y, Patch AM, Grabs R,
Wang J, Lynn FC, et al. Rfx6 directs islet formation and insulin production in
mice and humans. Nature. 2010;463:775–80.
35. Spiegel R, Dobbie A, Hartman C, de Vries L, Ellard S, Shalev SA. Clinical
characterization of a newly described neonatal diabetes syndrome caused
by RFX6 mutations. Am J Med Genet A. 2011;155A:2821–5.
Yau et al. Diagnostic Pathology  (2017) 12:1 Page 7 of 7
